(Yicai Global) Nov. 2 -- Shares of Eyebright Medical Technology moved up for the second straight day after the Chinese ophthalmic instrument supplier said its novel lens implant has gained the green light to go to market, marking the first domestically developed multifocal lens for cataract patients.

Eyebright's stock price [SHA: 688050] surged as much as 5.6 percent to CNY224.60 (USD30.90) intraday as of 2.46 p.m. The shares have risen by nearly 10 percent this year.

The intraocular lens, developed by Eyebright, is a pioneering product in China and it will be used to correct vision in adults with cloudy areas in the lens of their eyes, the National Medical Products Administration announced on Oct. 31. After surgery, the product provides patients with focal points near and far, overcoming shortcomings of monofocal intraocular lenses.

Until now, all multifocal intraocular lenses used in ophthalmic surgeries in China have been imported so the new product will fill a domestic gap in products and technologies, the producer said yesterday, without predicting the impact on its business performance.

As the population is aging, the number of cataract patients is rising significantly. The number of Chinese people at risk of cataracts is 140 million, and the related treatment market tallies around CNY10 billion (USD1.4 billion), Guosen Securities wrote in a recent research report.

Editor: Emmi Laine, Xiao Yi